This could lead to cell-based regenerative therapies that do not require immunosuppression, significantly improving patient outcomes. Creative Medical ... Data Safety Monitoring Board (DSMB ...

Creative Medical Technology (CELZ ... further optimizing therapeutic outcomes. The Data Safety Monitoring Board and the Institutional Review Board have already approved the new dosing strategy ...

The promising results represent a potential breakthrough in diabetes care, especially for patients who may not benefit from autologous therapies. Creative Medical Technology is now preparing to ...